CLINICAL NEWS
amplification of PD-L1/PD-L2, with
69 percent of cells having at least six
copies per cell.
• Case 3: An 80-year-old woman
with mediastinal gray-zone
lymphoma (confirmed after a
biopsy of an axillary lymph node
showed an immunophenotype
intermediate between DLBCL
and cHL, which was positive
treatment. Immunohistochemical
analysis showed focal membranous
PD-L1 expression.
for CD20, CD30, and CD15)
relapsed after dose adjusted
EPOCH-R and experienced disease
progression following treatment
with brentuximab; a combination
of rituximab, gemcitabine, and
oxaliplatin; and mediastinal
radiation. After receiving
nivolumab, she had a complete
metabolic response and continues
to be in remission after 161 days of
“These findings suggest that PD-1
inhibitors may be therapeutically
important for mediastinal gray-zone
lymphoma, which is more resistant
to treatment than cHL or primary
mediastinal B-cell lymphoma,” Dr.
Melani wrote. “The high frequency of
Clinical study results in children and adults receiving
prophylactic treatment over a 6-month period 1,2
The efficacy, safety and PK of ADYNOVATE were evaluated in 2 multicenter, open-label clinical studies. The pediatric
study of children <12 years of age (N=66) evaluated the immunogenicity, efficacy, PK (as compared to ADVATE ®
[Antihemophilic Factor (Recombinant)]), and safety of ADYNOVATE twice-weekly prophylaxis (40-60 IU/kg) and
determined hemostatic efficacy in the treatment of bleeding episodes for 6 months. The pivotal trial of children and
adults ≥12 years (N=137) evaluated ADYNOVATE twice-weekly prophylaxis (40-50 IU/kg) vs on-demand (10-60 IU/kg)
treatment, and dete